Details of the Drug
General Information of Drug (ID: DMM6CJI)
Drug Name |
11-keto-beta-boswellicacid
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
11-Keto-beta-boswellic acid; UNII-0S3BIF6H0Q; 11-Keto Boswellic Acid; 0S3BIF6H0Q; 17019-92-0; CHEMBL437964; 11-Oxo-beta-boswellic acid; (4R)-3alpha-hydroxy-11-oxo-urs-12-en-23-oic acid; Keto-b-boswellic acid; 3alpha-Hydroxy-11-oxours-12-en-24-oic acid; 11-Oxo-; 11-Keto-; BETA-BOSWELLIC ACID,11-KETO; A-Hydroxy-11-oxours-12-en-24-oic acid; 11-Oxo-b-boswellic acid; 11-Keto-b-boswellic acid; SCHEMBL4388405; (3alpha,4beta)-3-Hydroxy-11-oxours-12-en-23-oic acid
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 470.7 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 7.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||